$MNOV breakout $2.35


Website

Shares Outstanding: 24.15M
Float: 21.01M


10-Q 8/13/14

Recent trades


Press Releases
Monday, September 1, 2014
MediciNova to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF)GlobeNewswire

Monday, August 25, 2014
MediciNova to Initiate Clinical Trial of MN-166 (ibudilast) in ALSGlobeNewswire

Monday, August 18, 2014
MediciNova Announces Positive Interim Results of Phase 2a Study of MN-166 (ibudilast) in Opioid DependenceGlobeNewswire

Monday, August 11, 2014
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Nonalcoholic Fatty Liver DiseaseGlobeNewswire

Tuesday, August 5, 2014
MediciNova Announces Positive Results of MN-001 in Advanced NASH Mouse Model; MediciNova Requests a Meeting With FDAGlobeNewswire

Monday, July 7, 2014
MediciNova to Present Data on MN-001 for the Treatment of NASH (Nonalcoholic Steatohepatitis) During the JDDW 2014 (Japan Digestive Disease Week 2014)GlobeNewswire

Wednesday, June 11, 2014
MediciNova Announces Positive Results in Study of MN-001 in Mouse Model of Pulmonary FibrosisGlobeNewswire

Tuesday, April 8, 2014
Treatments for Non-Alcoholic Steatohepatitis Making Clinical StridesAccesswire